Table 3.

Confirmed best overall response according to RECIST v1.1

Dose levelTumor typeConfirmed best overall responseTotal number of M7824 InfusionsStill on active treatmentReason for treatment discontinuation
0.3→10 mg/kgAnalPR14Yes
0.3→10 mg/kgCervix uteriPD2NoPD
0.3→10 mg/kgColorectalPD6NoAEa
1 mg/kgAdenoid cystic carcinomaPD4NoPD
1 mg/kgBronchopulmonary carcinoidSD14NoOther
1 mg/kgPancreaticPD6NoPD
3 mg/kgPancreaticPR14NoAE
3 mg/kgPancreaticSD6NoOther
3 mg/kgPancreaticSD12NoPD
10 mg/kgColorectalPD3NoPD
10 mg/kgAppendicealSD7NoPD
10 mg/kgCervix uteriCR21NoAE
20 mg/kgCervix uteriPD3NoPD
20 mg/kgChordomaPDb6NoPD
20 mg/kgPancreaticSD8NoPD
20 mg/kgAdenoid cystic carcinomaPD3NoPD
20 mg/kgCervix uteriSD2NoAE
20 mg/kgAnalPD3NoPD
20 mg/kgSmall bowelNE2NoPD
  • Abbreviations: NE, not evaluable; RECIST, Response Evaluation Criteria In Solid Tumors.

  • aUnrelated to study treatment.

  • bDisease progression confirmed on day 85, and treatment was discontinued; however, at a follow-up visit on day 280, a restaging scan showed a 45% decrease in tumor burden despite no further therapeutic interventions after discontinuing M7824.